Take over 20% gains on Isis Pharmaceuticals (ISIS)
Today's Financial News - Posted April 17, 2009
If you bought Isis Pharmaceuticals at our recommended price of under $13, it’s time to gather in the gains!
by Laura Cadden, TodaysFinancialNews.com
Baltimore — (TFN): Back in mid-December, I encouraged TFN readers to buy Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) under $13 and look for double-digit gains to rack up fast.
By January 6 we’d hit over 10%, but I thought we could do better. I recommended that investors hold on to their shares for gains of 20%.
Their unique approach to treating illness with antisense technology was simply that promising.
Today we’ve arrived: I recommend you sell your shares of Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) and enjoy your gains.
Next Article: Back-door nationalization: A no-win situation for investors
One Response to “Take over 20% gains on Isis Pharmaceuticals (ISIS)”
Your comments are welcome
Follow TFN via RSS or Twitter |
 |
 |
 |
Advertisement
Latest Headlines
- The Big Picture for Sinobiopharma, Inc. (SNBP)
- Beazer Homes USA, Inc. (BZH) and Hovnanian Enterprises, Inc. (HOV) up despite horrid housing news
- The FDA catalyst: 2010 moves in MannKind (MNKD), Roche Holding (RHHBY), Acorda Therapeutics (ACOR) show it still works!
- Steepest drop since Feb. 2009: Here we go again!
- Is the silver run over? Coeur d’Alene Mines (CDE), Silver Wheaton (SLW), Alto Group (ALTO), Hecla Mining (HL), Endeavour Silver (EXK) close down
May 1st, 2009 at 9:53 am
It is not the time to sell Isis, it is the time to buy. Isis has good cash flow and many products in the pipe line. I have been in the medical field for 19 years and I see Isis where the biologics were over 10 yrs. ago (enbrel) big block buster drug.
This stock is going to move once mipomersen is approved, to many side effects with those statin drugs.
MJ